Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 12/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7790361 | 0.83 | TACR1 (0.61) | TACR1 | |
| SCHEMBL7797019 | 0.79 | TACR1 (0.55) | TACR1TBXAS1 | |
| SCHEMBL7797108 | 0.79 | TACR1 (0.57) | TACR1 | |
| SCHEMBL7790383 | 0.77 | KMT2A (0.54) | KDM4ETP53RXFP1 | |
| SCHEMBL7798278 | 0.77 | TACR1 (0.61) | TACR1KDM4ETBXAS1 | |
| SCHEMBL29757657 | 0.77 | MCL1 (0.50) | KDM4EMAPTEGFR | |
| SCHEMBL7796987 | 0.76 | TBXAS1 (0.71) | TACR1TBXAS1 | |
| SCHEMBL7796991 | 0.76 | TACR1 (0.60) | TACR1TBXAS1 | |
| SCHEMBL7797116 | 0.75 | TACR1 (0.62) | TACR1MAPTTBXAS1 | |
| SCHEMBL7797113 | 0.75 | TBXAS1 (0.52) | TACR1TBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010039286-A1 | 2-aryl indole derivatives and their use as therapeutic agents | DINNELL KEVIN (GB) | 2001-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010039286-A1 | 2-aryl indole derivatives and their use as therapeutic agents | IDO1, IDO2, CNR2 | TACR1 1285/4885KDM4E 2526/4885MAPT 3701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.